RecruitingPhase 2NCT06405607

Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

Psilocybin vs Ketamine for Alcohol Use Disorder

Sponsor

University of Iowa

Enrollment

80 participants

Start Date

Jun 12, 2025

Study Type

INTERVENTIONAL

Conditions

Alcohol Use Disorder Alcohol Dependence Alcohol Abuse

Summary

This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg/kg dose of ketamine.

Eligibility

Min Age: 21 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ketamine and a drug called Psilocybin for people with alcohol abuse, alcohol dependence, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPsilocybin

30 mg single dose

DRUGKetamine

0.75 mg/kg weight-based single dose

Locations(1)

University of Iowa Health Care

Iowa City, Iowa, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06405607

Related Trials

Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)

NCT056773211 location

Tirzepatide in MetALD

NCT070468191 location